- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02181972
Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults
July 17, 2014 updated by: Boehringer Ingelheim
Efficacy and Safety of Gingko Biloba Film-coated Tablets (2 x 60 mg Daily p.o.) in Improving Cognitive Functions and Neuropsychological Functioning of Middle-aged Cognitively Intact Adults: a Double-blind, Placebo-controlled, Parallel Group, Randomised Trial
The primary objective of this study was to assess the efficacy and safety of Gingko biloba film-coated tablets in improving cognitive function and neuropsychological functioning of middle-aged cognitively intact adults.
Study Overview
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female healthy subjects with no known clinically significant pathology as assessed by the investigator
- Mini-Mental State Examination (MMSE) score ≥ 28
- Age range: 40 to 60, inclusive
- Females must test negative for pregnancy
- Clinical laboratory tests must be within normal limits or, if out of normal range, clinically acceptable to the Investigator
- Urine drug screen for illicit drugs must be negative at screening
- Subjects must have given written informed consent in accordance with ICH-GCP (International Conference on Harmonization - Good Clinical Practice) and local laws and regulations
Exclusion Criteria:
- Any serious disorder that may interfere with his/her participation in the trial and the evaluation of the safety of the test drug
- Pre-treatment and/or concomitant treatment with any drug that may influence the trial symptomatology and may interfere with the evaluation of cognitive function
- Alcohol and drug abuse according to DSM-IV (Diagnostic and Statistics Manual, Version IV)
- Individuals drinking more than 6 cups of coffee or tea/day
- Individuals smoking more than 10 cigarettes/day
- Subjects who in the opinion of the investigator are heavy users of other tobacco or nicotine products
- Subjects currently taking a cognition enhancing substance, including any Ginkgo or ginseng product
- Any subject regularly taking a medication who might stop doing so at some time during the active dosing phase, if the medication is deemed by the investigator to influence the outcome of the trial
- Female subjects of child-bearing age who are not using adequate means of birth control
- Pregnancy and/or lactation
- Any subject who, according to the Investigator, is unable to perform the CDR cognitive tests or the neuropsychological tests in a satisfactory and consistent manner
- Relevant allergy or known hypersensitivity to the investigational product or its excipients
- Individuals under anticoagulant treatment
- Individuals with a current disorder likely to modify computerised cognitive testing
- Individuals having a history of cancer (any type, excluding surgically removed and treated basal cell carcinoma)
- Clinically significant and not treated thyroid disease
- Participation in another clinical trial within the last 3 months prior to the start of the study and concurrent participation in another clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: Gingko biloba
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes from baseline of the cognitive test/CDR (Cognitive Drug Research) factor "Power of Attention)
Time Frame: pre-dose and 2, 4, 6 hours post-dosing at baseline and day 56
|
pre-dose and 2, 4, 6 hours post-dosing at baseline and day 56
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes from baseline in CDR factors
Time Frame: pre-dose and 2, 4, 6 hours post-dosing at baseline, days 28 and 56
|
pre-dose and 2, 4, 6 hours post-dosing at baseline, days 28 and 56
|
Changes from baseline in Stroop Colour and Word Test
Time Frame: Baseline and day 56
|
Baseline and day 56
|
Changes from baseline in the Selective Reminding Test
Time Frame: Baseline and day 56
|
Baseline and day 56
|
Changes from baseline in the Trail Making Test (Part A and B)
Time Frame: Baseline and day 56
|
Baseline and day 56
|
Number of patients with adverse events
Time Frame: up to 56 days
|
up to 56 days
|
Number of patients with clinically significant changes in vital signs
Time Frame: Baseline, days 28 and 56
|
Baseline, days 28 and 56
|
Number of patients with abnormal changes in laboratory parameters
Time Frame: Baseline and day 56
|
Baseline and day 56
|
Assessment of tolerability by subject on a 4-point scale
Time Frame: Days 28 and 58
|
Days 28 and 58
|
Assessment of tolerability by investigator on a 4-point scale
Time Frame: Days 28 and 58
|
Days 28 and 58
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2002
Primary Completion (Actual)
November 1, 2002
Study Registration Dates
First Submitted
July 2, 2014
First Submitted That Met QC Criteria
July 7, 2014
First Posted (Estimate)
July 8, 2014
Study Record Updates
Last Update Posted (Estimate)
July 18, 2014
Last Update Submitted That Met QC Criteria
July 17, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 1118.2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States